Peptide Marketplace — Session Notes & Action Items

Date: April 26, 2026 Participants: Alton, [partner], Jack (joined late), Monica (brief) Context: Pressure-testing the peptide venture thesis against adversarial research and OIG 25-08

Where we landed

Conviction level: 6–7/10, up from a starting wobble. Started the session at 6, dipped during the disconfirmation read, climbed back to 7 after working through the marketplace model. Not committing yet. Still a one-way-door decision that needs more validation.

The thesis we now believe:

Peptides are genuinely valuable for people, even without robust FDA approval. Long tail risks exist but real-world tolerance is good. Millions of people are already using research-grade peptides with reasonable outcomes.
The problem is the system, not the product. Information is fragmented, vibe-coded wellness blogs dominate search results, and there's no trust layer.
A vendor-neutral marketplace + clinical software + trust/info layer, done well, is an 8–9/10 idea. Done poorly, it's a felony.
The legal architecture only works as a buyer-side technology fee model with zero pharmacy economic relationship. Anything else (commissions, markups, kickbacks) exposes us to AKS / state patient-brokering felony charges we had no idea existed before today.

The thesis we no longer believe:

Single-pharmacy partnership with Raja is viable. It isn't. Need multiple suppliers.
Per-Rx fee paid by the pharmacy is fine. It isn't — that's the AO 25-08 fact pattern.
Healthcare is "just like SaaS." It's not. The compliance and legal stack are real and meaningful costs.
We can bootstrap this. We can't. This is a venture-funded business or it's nothing.

Key insights from the session

On the disconfirmation research

The adversarial research surfaced things we wouldn't have caught on our own. The Done Health founder being convicted in November 2025 was a real "glad we did our homework" moment.
Most of the disconfirmation memo's threats are real but addressable. The two that aren't: PCAC trajectory risk (out of our control) and team gaps (solvable with money).
The pattern-match to Olive AI / Truepill / Done Health / Hims–Novo is sobering but not fatal. Those companies all had specific structural failures that a marketplace model with multi-supplier neutrality avoids.
Hems shutting down compounded GLP-1 in March 2026 (partnered with Novo for branded Wegovy) is the contemporary template. We should study what they kept and what they killed.

On the legal structure

OIG 25-08 was the wake-up call. The original $35 per-Rx fee paid by pharmacy structure was a felony fact pattern. We had no idea.
The only model that works: provider pays platform a flat per-order processing fee + SaaS subscription. Pharmacies pay zero, forever. Multi-supplier, neutral routing, audit-logged.
Cash-pay does not save us from state patient-brokering laws (Florida §817.505, California §650, Texas Occ. §102.001). The cash-pay carve-out is narrower than founders typically assume.
We need a healthcare lawyer. This is not a "maybe later" hire — it's a Month 1 engagement, even if just on retainer.

On Jack's input

Jack confirmed competitors (Beads, Healing Biologics) operate multi-vendor marketplaces, but the commission structure they use ("pharmacy pays platform 50% of cost") is exactly what AO 25-08 says is suspect. Jack's view that "I don't know how frowned upon that really is" is the founder hubris our research warned about.
The "purchase agreement + markup" model Jack described is also problematic — it makes us an unlicensed wholesaler, which has its own state pharmacy board exposure.
Useful data point from Jack: the actual problem clinics have isn't pricing or supply, it's workflow. Ordering peptides is hard, prescriptions are hard, lead times are unreliable. That's the wedge.
Healing Biologics' UI ("log in, look up drug, see 3 lines from different vendors with prices, click to order") is functionally what we need to build, with our own trust/marketing/agentic layer on top.

On the international angle

If the US market gets restrictive, the same software stack templated for Mexico, Brazil, Argentina, Peru, Spain is a real Plan B / expansion path. Different rules, same tech, real demand.
Partner with Novo / Lilly internationally where compounding is restrictive but their branded products dominate. Become a delivery infrastructure layer rather than a compounding-dependent business.
Don't build for this now. Build for it as optionality.

On the Raja conversation

Raja and Pradeep are pharmacy nerds looking for a tech founder. We are the tech founder. The dynamic is real.
They've vibe-coded a 2010-era order management system. The agentic optimization opportunity is large — most of those workflows can be automated. That is what we sell.
We did not sign anything. Good. Should request a distribution agreement to look at, but make clear we're shopping multiple pharmacies, not exclusive.
Raja becomes one of N suppliers, not the supplier. This needs to be communicated cleanly when we re-engage.

On the build

Theoretical site / vibe-coded prototype tonight. The website is the pitch deck. Anyone landing on it should know whether we're legit.
Multi-vendor marketplace + practice management + trust layer is technically buildable. "If we can build missiles, we can build software." The question is whether it's the right idea, not whether it's possible.
Agentic workflow optimization is the differentiator and the pricing justification. Subscription + consumption pricing makes sense for it.

The model — current state

Buyer-side technology fee marketplace.

Provider pays platform: SaaS subscription ( $499–$ 1,999/mo + per-provider) + per-order processing fee ($8–15 flat)
Provider pays pharmacy: direct, for the actual peptide
Pharmacy pays platform: $0, forever, no exceptions
Routing: neutral algorithm, multi-supplier, audit-logged, provider can override
Fee FMV-defended on services rendered (payment processing, routing infrastructure, fraud screening, compliance logging, support)

Three things we need to prove (the de-risking gate):

Demand — paying clinics, not LOIs
Multiple compounding pharmacies — 3+ signed fulfillment agreements with zero economic flow to platform
Marketplace model in production — live routing, audit logs, FMV documentation

Disagreements / open tensions

Alton: "Just ordering prescriptions" critique from research is 2/10 — we're building end-to-end practice management with marketplace + trust layer, not just an ordering tool. Disagree with research's framing here.
Partner: "Want to make sure our value prop is rock solid before we sign clinics." Trust layer + marketing + agentic workflows — which one is the headline differentiator?
Unresolved: Is the headline value prop (a) trust/info layer, (b) marketing engine for clinics, (c) agentic workflow optimization, or (d) all three combined? Need to pick one for positioning, even if we build all three.
Unresolved: Console (existing product, real users) vs. peptide pivot vs. B2B SaaS pivot. Three ideas competing. Founder friend pushing for "just fix Console."

Decision framework going forward

We are at a fork:

Option A: Pursue peptide marketplace. High ceiling (8–9/10 if executed well), high risk (legal + regulatory + execution), requires venture funding, requires healthcare legal counsel, requires team build.
Option B: Fix Console. Existing users, founder friend would pay for it, lower ceiling, much lower risk.
Option C: Pivot to B2B SaaS GTM tooling. Different market entirely.

Bezos one-way-door framing applies. Spending another 4 weeks validating Option A before deciding is cheap. Committing to Option A without validation is expensive.

Action items

This week (Alton)

Tonight: Vibe-code the theoretical marketplace site. Landing page = pitch deck. Test whether the model communicates clearly to a stranger in 30 seconds.
Build pharmacy target list. 15+ second/third-tier 503A operators. Hallandale, Revelation, BelmarRx, Wells, AnazaoHealth, College, MediVera, Valor, Lifecycle, Precision, plus 5 more from the 7,500 in the US.
Pull pricing data on 10 peptides across 5 pharmacies. BPC-157 5mg, semaglutide, NAD+, glutathione, tirzepatide, ipamorelin, CJC-1295, TB-500, sermorelin, GHK-Cu. If price spread <10%, marketplace thesis weakens.
Request distribution agreement from Raja. Don't sign. Read it. Use it as a benchmark for what these contracts look like.
Draft clinic pilot pitch. What does a clinic get for $499/mo +$ 8/order during pilot? Quantify time savings, price comparison, documentation, compliance audit trail.
Check polymarket / prediction markets for PCAC July 2026 odds. If insider sentiment is "high chance of approval" but markets disagree, that's a tradable edge regardless.

This week (partner)

Talk to med spas. Talk to OBGYNs. Talk to clinics. Cold call, cold email. Validate that the wedge (workflow pain in peptide ordering) is real.
Schedule call with Louie (former Formula CEO). He's bullish, runs peptide-focused med spas, can validate clinic-side pain points. High-value conversation.
Schedule call with Michael Bennett. Validate concerns from disconfirmation research with someone in the field.
Research escripts pricing model. How does GoodRx actually structure their business model? What's the cleanest comparable?
Research Healing Biologics in detail — UI, pricing, vendor count, customer count if findable. They're the closest existing comparable.

This week (joint)

Work session with Jack. Walk through marketplace model, validate against what he's seen Beads do, get his read on workflow pain.
Decide on primary value prop positioning: trust layer, marketing, agentic workflows, or composite. Need this for the website.
List the questions for Jack's healthcare lawyers. Top of list: does the buyer-side technology fee model actually clear AO 25-08 + state patient-brokering laws?

Next 30 days

Recruit 5 clinics willing to pay for an MVP at discounted launch pricing ( $299/mo +$ 8/order).
Sign 3 non-exclusive fulfillment agreements with 503A pharmacies. Zero economic flow to platform.
Build duct-tape MVP. Retool/Airtable frontend, manual or semi-automated routing on backend, real ordering, real audit logs, real per-order fee billing.
Engage healthcare counsel on retainer. Frier Levitt or Hyman Phelps. Goal: scope an OIG advisory opinion request.
Draft FMV memos for every fee component before finalizing pricing.

60–120 days

Get to $10K MRR with 5+ paying clinics, 3 active pharmacies, 200+ orders/month, 80%+ M2 retention.
Pull pricing variance data from real orders. Validate or kill the multi-supplier price discovery thesis.
Begin OIG advisory opinion request drafting with counsel.
Capture one competitive bidding event (clinic order, multiple pharmacies bid, lower price wins) for the pitch deck.

Ongoing / when relevant

Don't tell Monica too much detail until we have answers. We're "doing homework" right now. She's supportive but cautious.
Don't sign anything with Raja, Pradeep, or any single pharmacy that implies exclusivity or per-Rx economic flow.
Re-evaluate at the 90-day mark: do we have $10K MRR? Do we have 3 pharmacies? Does the marketplace work? If yes to all three, raise pre-seed. If no, return to the fork (Console, B2B SaaS, kill).

Things to NOT do

Don't do per-Rx fees from pharmacies. This is the felony fact pattern.
Don't sign exclusive deals with any single pharmacy. Single-supplier risk + AKS exposure compound.
Don't take pharmacy money for "marketing co-op" or "data fees" or anything else. Side deals are how marketplaces become prosecutions.
Don't accept Jack's "I don't know how frowned upon that really is" framing on commission structures. That's the founder hubris that killed Done Health.
Don't pitch the venture publicly until the legal structure is reviewed. No tweets, no LinkedIn posts about "the peptide marketplace we're building." Stealth until counsel signs off on the architecture.
Don't treat the disconfirmation research as a problem to dismiss. Most of its concerns are real. The exercise of taking them seriously is what gets the round funded.

Open questions for next session

What is the headline value prop? Trust, marketing, agentic, or composite?
Can we get 3 pharmacies signed in 30 days, or is the timeline longer?
What does the duct-tape MVP actually need to do on day 1?
Console vs. peptides vs. B2B SaaS — when do we make the irreversible call?
Healthcare counsel — Frier Levitt vs. Hyman Phelps vs. Jack's lawyers? Need to pick.
International expansion — when does this become a real workstream vs. theoretical optionality?

Honest read

We started the session worried we were about to walk into a felony. We left believing there's a defensible legal architecture, a real wedge (workflow pain in clinic peptide ordering), and a fundable business if execution is clean.

The biggest risk now isn't legal — it's commercial. Will pharmacies participate at zero economic relationship? Will clinics pay $499 +$ 8/order? Does multi-supplier price discovery actually deliver value? Those are answerable in 60–90 days with modest spend.

If we hit the de-risking metrics, we have a pre-seed story that doesn't depend on hand-waving. If we don't, we've spent 90 days and learned the answer was no, and we go back to the fork with better information.

Worth the 90 days.